Serum Institute of India (SII) on Wednesday said its vaccine to protect against the five predominant causes of meningococcal meningitis in Africa has been prequalified by the World Health Organisation. MenFive has been developed through a 13-year collaboration between Serum and PATH, a global nonprofit, with crucial funding from the UK government's Foreign, Commonwealth and Development Office. WHO prequalification, which ensures a vaccine meets strict international quality, safety, and efficacy standards, was supported by extensive clinical studies in The Gambia, India, and Mali. Importantly, prequalification allows MenFive to be procured by United Nations agencies and Gavi, the vaccine alliance. "As the first conjugate vaccine to safeguard against the five predominant causes of this deadly disease, MenFive offers hope for a future free from annual outbreaks and epidemics in the African meningitis belt," SII CEO Adar Poonawalla said in a statement. The vaccine protects against ...
The company's chief executive officer Stephane Bancel is in China and the deal is expected to be signed on Wednesday
It is estimated that 101 million people in India - around 10 per cent of the country's population - are suffering from diabetes
DCGI has granted Emergency Use Authorisation to India's first mRNA-based Omicron booster vaccine and it is likely to be rolled out in 2-3 weeks, Gennova Biopharmaceuticals announced on Tuesday
A more equitable access to Covid vaccines could have prevented more than 50 per cent of COVID-19 deaths in 20 lower income countries, according to a new study. Scientists from the Northeastern University, US, have estimated 518,000 deaths could have been averted if the 20 countries in the study had received the vaccines at the same time as the US and other high income countries and in comparable quantities, using a computational epidemic model. The countries included in the study were Angola, Kenya, Ghana, Cote d'Ivoire, Mozambique, Uganda, Rwanda, Zambia, Egypt, Morocco, Afghanistan, Pakistan, Sri Lanka, Bangladesh, Indonesia, Bolivia, El Salvador, Honduras, Philippines and Kyrgyzstan. The study is published in the journal Nature Communications. The estimation that "thousands and thousands" of lives were lost to vaccine inequity was a "punch in the stomach," said Alessandro Vespignani, director of Northeastern's Network Science Institute and the study's co-author. "We need to hav
Better access to vaccines could have prevented more than 50 per cent of Covid-19 deaths in 20 lower income countries, scientists contend in a new study
US drugmaker Pfizers and British pharma major GSK are likely to face significant competition in the respiratory syncytial virus (RSV) vaccine market, according to a report on Tuesday
Govt terms breach reports on Telegram 'mischievous'
Mandaviya, in his address, highlighted the importance of collaborative research in mitigating and responding effectively to global health crises
India administers two kinds of polio vaccines to children, first is the inactive polio vaccine (IPV) and the other is the bio-oral polio vaccine (bOPV) which contains live viruses to provide immunity
Uttarakhand, Maharashtra and Karnataka lead the way; 1.9 million vaccine doses administered in new cycle
The US approved the first vaccine for RSV on Wednesday, shots to protect older adults against a respiratory virus that's most notorious for attacking babies but endangers their grandparents, too. The Food and Drug Administration decision makes GSK's shot, called Arexvy, the first of several potential vaccines in the pipeline for RSV to be licensed anywhere. The move sets the stage for adults 60 and older to get vaccinated this fall but first, the Centers for Disease Control and Prevention must decide if every senior really needs RSV protection or only those considered at high risk from the respiratory syncytial virus. CDC's advisers will debate that question in June. After decades of failure in the quest for an RSV vaccine, doctors are anxious to finally have something to offer especially after a virus surge that strained hospitals last fall. This is a great first step ... to protect older persons from serious RSV disease, said Dr. William Schaffner, medical director of the Natio
Highlighting the country's strides in the pharma and biotechnology sector, Union Minister Jitendra Singh said the Indian vaccine market is expected to reach a valuation of Rs 252 billion by 2025
Shingrix is for the prevention of shingles or what is also known as herpes zoster and also post-herpetic neuralgia in people aged 50 and above, says GSK Pharmaceuticals MD Bhushan Akshikar
Doctors say they are seeing an increase in children with Covid infection
Public health policy must respond for the long term
Tamil Nadu, Kerala, Puducherry and Haryana are some of the states to have brought back fresh Covid-19 protocol, especially the mask mandate
Initiates talks with private hospitals for dispatching existing Covovax stock; Conducts in-vitro studies on human blood samples for neutralising antibody titres against XBB in India
Bihar Chief Minister Nitish Kumar on Friday urged the Centre to provide fresh stocks of COVID vaccine vials so that administering of jabs, which is currently on hold, could be resumed. Talking to reporters here on the sidelines of a function, he also asserted that his government was "alert" in view of rising incidence of COVID cases in some parts of the country, though Bihar was not one of them. "Our testing rate is much higher than the national average, which is six lakh tests per one million people. We are conducting eight lakh tests. Bihar accounts for about one fourth of the total number of tests conducted across the country", claimed Kumar. He underscored that the current spike was noticed in those parts of the country which were the worst affected when the coronavirus had caused a global pandemic. "In Bihar cases are very few but we are alert, nonetheless. In places like hospitals wearing of masks is being reinforced. We were also carrying out vaccination till our supply drie
230 of the 296 sites are private; people can now opt for mix-and-match doses of Corbevax and iNCOVACC